SAR 55.9
(2.57%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 1.81 Million SAR | -37.3% |
2022 | 2.89 Million SAR | 9.26% |
2021 | 2.64 Million SAR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 113.98 Thousand SAR | 0.0% |
2024 Q1 | 113.98 Thousand SAR | -45.15% |
2023 Q3 | 207.79 Thousand SAR | -57.99% |
2023 Q4 | 207.79 Thousand SAR | 0.0% |
2023 FY | 1.81 Million SAR | -37.3% |
2023 Q2 | 494.6 Thousand SAR | -0.0% |
2023 Q1 | 494.6 Thousand SAR | -45.7% |
2022 FY | 2.89 Million SAR | 9.26% |
2022 Q4 | 910.82 Thousand SAR | 0.0% |
2021 FY | 2.64 Million SAR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 78.24 Million SAR | 97.684% |
Al-Dawaa Medical Services Company | 466.68 Million SAR | 99.612% |
Nahdi Medical Company | 960.95 Million SAR | 99.811% |
Almujtama Alraida Medical Co. | 13.94 Million SAR | 87.006% |